Search Results - "Hausmaninger, H."

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial by WINDBICHLER, G. H, HAUSMANINGER, H, STUMMVOLL, W, GRAF, A. H, KAINZ, C, LAHODNY, J, DENISON, U, MÜLLER-HOIZNER, E, MARTH, C

“…Intraperitoneal treatment with interferon-gamma (IFN-gamma) has been shown to achieve surgically documented responses in the second-line therapy of ovarian…”
Get full text

Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy by Fridrik, M. A., Greil, R., Hausmaninger, H., Krieger, O., Oppitz, P., Stöger, M., Klocker, J., Neubauer, M., Helm, W., Pont, J., Fazeny, B., Hudec, M., Simonitsch, I., Radaszkiewicz, T.

Get full text

A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer by SCHIPPINGER, W, JAGODITSCH, M, HOLZBERGER, P, MITTLBÖCK, M, JAKESZ, R, SORRE, C, GNANT, M, STEGER, G, HAUSMANINGER, H, MLINERITSCH, B, SCHABERL-MOSER, R, MISCHINGER, Hj, HOFBAUER, F

“…The purpose of this trial was to examine the efficacy of the addition of levamisole (LEV) or interferon alfa (IFN) to an adjuvant chemotherapy with…”
Get full text

Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer by Jakesz, R, Hausmaninger, H, Samonigg, H

“…Comparisons between the effects exerted by adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)-based polychemotherapy and endocrine treatment in…”
Get full text

A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer by Paridaens, R., Van Aelst, F., Georgoulias, V., Samonnig, H., Cocquyt, V., Zielinski, C., Hausmaninger, H., Willemse, P., Boudraa, Y., Wildiers, J., Ramazeilles, C., Azli, N.

“…Background: This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line…”
Get full text

Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients by Kucera, E., Speiser, P., Gnant, M., Szabo, L., Samonigg, H., Hausmaninger, H., Mittlböck, M., Fridrik, M., Seifert, M., Kubista, E., Reiner, A., Zeillinger, R., Jakesz, R.

“…The aim of our study was to evaluate if p53 mutations, especially those in the L2/L3 domains of the p53 gene, add prognostic information for node-positive and…”
Get full text

Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study by Marth, C, Windbichler, G H, Hausmaninger, H, Petru, E, Estermann, K, Pelzer, A, Mueller-Holzner, E

“…We have previously shown that interferon-gamma 1b (IFN-gamma) in combination with cyclophosphamide and cisplatin significantly prolongs progression-free…”
Get more information

Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node–Positive Breast Cancer by JAKESZ, R, HAUSMANINGER, H, FRIDRIK, M, MLINERITSCH, B, STEINDORFER, P, MITTLBÖCK, M, STEGER, G, HAIDER, K, KUBISTA, E, SAMONIGG, H, GNANT, M, MANFREDA, D, TSCHURTSCHENTHALER, G, KOLB, R, STIERER, M

“…To evaluate the outcome in patients with stage II hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in…”
Get full text

A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML) by Kühr, T., Burgstaller, S., Apfelbeck, U., Linkesch, W., Seewann, H., Fridrik, M., Michlmayr, G., Krieger, O., Lutz, D., Lin, W., Pont, J., Köck, L., Abbrederis, K., Baldinger, C., Buder, R., Geissler, D., Hausmaninger, H., Lang, A., Zabernigg, A., Duba, C., Hilbe, W., Eisterer, W., Fiegl, M., Greil, R., Gastl, G., Thaler, J.

“…This multicenter randomized phase III study was designed to compare the efficacy and toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10 mg/m 2…”
Get full text

Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure by Mlineritsch, B, Mayer, P, Rass, C, Reiter, E, Russ, G, Vesenmayer, G, Oberaigner, W, Hausmaninger, H

“…Aim of this study was to evaluate the clinical benefit and the toxicity of pegylated liposomal doxorubicin. Patients with metastatic breast cancer (n = 30) who…”
Get more information

Prognostic relevance of three histological grading methods in breast cancer by Latinovic, L, Heinze, G, Birner, P, Samonigg, H, Hausmaninger, H, Kubista, E, Kwasny, W, Gnant, M, Jakesz, R, Oberhuber, G

“…Histological grading is an important parameter for the risk assessment in patients with breast cancer. However, up to now differing grading methods are used…”
Get more information

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-α-2c in patients with advanced colorectal cancer: final results of a randomised phase III study by Hausmaninger, H, Moser, R, Samonigg, H, Mlineritsch, B, Schmidt, H, Pecherstorfer, M, Fridrik, M, Kopf, Ch, Nitsche, D, Kaider, A, Ludwig, H

“…5-Fluorouracil (5-FU) remains the mainstay of treatment for advanced colorectal carcinoma, although response rates are generally less than 20%. Improved…”
Get full text

Efficacy and toxicity of 2-chlorodeoxyadenosine (cladribine)—2 h infusion for 5 days—as first-line treatment for advanced low grade non-Hodgkin’s lymphoma by Fridrik, M.A, Jäger, G, Kienzer, H.R, Hausmaninger, H, Oppitz, P, Krieger, O, Zabernigg, A, Lang, A, Neubauer, M, Weidinger, G, Schiller, L, Seewann, H.L, Chott, A, Linkesch, W

“…2-Chlorodeoxyadenosine (Cladribine) is a new purine analogue with high activity in pretreated low grade non-Hodgkin’s lymphoma (NHL). To evaluate the efficacy…”
Get full text

Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients by Ploner, F, Jakesz, R, Hausmaninger, H, Kolb, R, Stierer, M, Fridrik, M, Steindorfer, P, Gnant, M, Haider, K, Mlineritsch, B, Tschurtschenthaler, G, Steger, G, Seifert, M, Kubista, E, Samonigg, H

“…A randomised, controlled clinical trial was initiated in 1984 to test whether 1 cycle of anthracycline-containing adjuvant chemotherapy improves the outcome of…”
Get more information

CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial by Fridrik, M A, Hausmaninger, H, Linkesch, W, Stöger, M, Sill, H, Neubauer, M, Seewann, H L, Klocker, J, Haidinger, R, Schiller, L, Pont, J, Raudaschl, G, Falk, M, Radaszkiewicz, T

“…This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in a multicenter setting of university and community…”
Get more information

Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients by Jakesz, R., Samonigg, H., Gnant, M., Kubista, E., Steindorfer, P., Hausmaninger, H., Sevelda, P., Tschurtschenthaler, B., Fridrik, M., Stierer, M., Kolb, R., Steger, G., the Austrian Breast Cancer Study Group

“…A randomised clinical trial was performed to test whether or not low-dose chemotherapy lasting only 35 days improves the outcome of breast cancer patients with…”
Get full text

Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer by SCHOPPMANN, Sebastian F, BAYER, Guenther, JAKESZ, Raimund, HORVAT, Reinhard, AUMAYR, Klaus, TAUCHER, Susanne, GELEFF, Silvana, RUDAS, Margaretha, KUBISTA, Ernst, HAUSMANINGER, Hubert, SAMONIGG, Hellmut, GNANT, Michael

“…The aim of this study was to investigate the prognostic relevance of lymphangiogenesis and lymphovascular invasion in a large cohort of breast cancer patients…”
Get full text

Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5 by JAKESZ, Raimund, HAUSMANINGER, Hubert, KWASNY, Werner, FRIDRIK, Michael, STEGER, Guenther, WETTE, Viktor, SAMONIGG, Hellmut, KUBISTA, Ernst, GNANT, Michael, MENZEL, Christian, BAUERNHOFER, Thomas, SEIFERT, Michael, HAIDER, Karin, MLINERITSCH, Brigitte, STEINDORFER, Peter

“…Effective adjuvant treatment modalities in premenopausal breast cancer patients today include chemotherapy, ovariectomy, and tamoxifen administration. The…”
Get full text

Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer by Hausmaninger, H., Lehnert, M., Steger, G., Sevelda, P., Tschurtschenthaler, G., Hehenwarter, W., Fridrik, M., Samonigg, H., Schiller, L., Manfreda, D., Haidinger, R., Kienzer, R., Kemmler, G.

“…The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic…”
Get full text

Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group by FILIPITS, Martin, POHL, Gudrun, SAMONIGG, Hellmut, JAKESZ, Raimund, RUDAS, Margaretha, DIETZE, Otto, LAX, Sigurd, GRILL, Renate, PIRKER, Robert, ZIELINSKI, Christoph C, HAUSMANINGER, Hubert, KUBISTA, Ernst

“…The multidrug resistance protein 1 (MRP1) is expressed in human breast cancer cells and may contribute to the clinical drug resistance of breast cancer…”
Get full text